Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Betta Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	527.19	471.68	752	731.28	791.99	1,346
Short-Term Investments	-	-	-	-	-	190
Trading Asset Securities	50.28	126.44	0.54	-	201.01	-
Cash & Short-Term Investments	577.47	598.12	752.54	731.28	993	1,536
Cash Growth	24.07%	-20.52%	2.91%	-26.36%	-35.35%	194.64%
Accounts Receivable	173.4	98.47	286.41	450.62	173.38	52.61
Other Receivables	41.39	1.83	2.61	49.7	40.75	6.81
Receivables	214.79	100.3	289.02	500.32	214.13	59.42
Inventory	333.25	290.09	327.5	372.17	293.32	188.59
Prepaid Expenses	-	-	0.2	-	-	-
Other Current Assets	233.21	235.82	156.62	129.06	153.49	63.91
Total Current Assets	1,359	1,224	1,526	1,733	1,654	1,848
Property, Plant & Equipment	2,985	3,009	2,574	2,056	1,331	775.72
Long-Term Investments	1,260	1,437	1,382	919.27	345.79	274.55
Goodwill	413.58	413.58	413.58	413.58	413.58	413.58
Other Intangible Assets	2,840	2,776	1,944	1,219	1,183	603.37
Long-Term Deferred Tax Assets	57.35	56.73	39.13	85.96	55.06	55.22
Long-Term Deferred Charges	201.47	383.53	1,219	1,444	1,252	1,171
Other Long-Term Assets	83.64	41.99	50.3	39.3	37.6	87.79
Total Assets	9,199	9,342	9,147	7,910	6,271	5,230
Accounts Payable	579.84	746.11	800.12	35.85	431.19	113.62
Accrued Expenses	251.16	285.53	357.82	419.11	357.02	187.53
Short-Term Debt	152.62	100.08	300.27	380.39	-	-
Current Portion of Long-Term Debt	694.39	639.85	301.25	-	-	-
Current Portion of Leases	34.7	33.03	4.6	4.16	4.88	-
Current Income Taxes Payable	8.31	4.26	0.07	0.04	10.68	27.54
Current Unearned Revenue	1.95	2.63	4.92	4.46	0.69	1.27
Other Current Liabilities	33.57	36.47	34.11	1,261	84.4	108.14
Total Current Liabilities	1,757	1,848	1,803	2,105	888.86	438.1
Long-Term Debt	1,491	1,552	1,816	656.03	-	2.6
Long-Term Leases	57.58	71.63	8.18	7.3	6.34	-
Long-Term Unearned Revenue	196.94	150.99	144.7	112.76	112	58.01
Long-Term Deferred Tax Liabilities	19.68	53.49	23.39	71.57	68.39	64.64
Other Long-Term Liabilities	-	-	-	-	510.06	521.99
Total Liabilities	3,522	3,676	3,795	2,952	1,586	1,085
Common Stock	420.73	418.49	418.49	417.47	415.39	413.16
Additional Paid-In Capital	2,035	1,945	1,945	1,860	1,932	1,793
Retained Earnings	2,890	2,834	2,503	2,181	2,139	1,883
Comprehensive Income & Other	247.97	375.78	384.48	390.99	74.64	52.28
Total Common Equity	5,594	5,574	5,251	4,849	4,561	4,141
Minority Interest	83.11	92.3	100.4	108.64	124.9	3.41
Shareholders' Equity	5,677	5,666	5,351	4,958	4,686	4,144
Total Liabilities & Equity	9,199	9,342	9,147	7,910	6,271	5,230
Total Debt	2,430	2,396	2,430	1,048	11.22	2.6
Net Cash (Debt)	-1,853	-1,798	-1,678	-316.59	981.77	1,533
Net Cash Growth	-	-	-	-	-35.97%	-
Net Cash Per Share	-4.37	-4.29	-4.00	-0.76	2.36	3.77
Filing Date Shares Outstanding	420.73	418.49	418.49	417.47	415.39	413.16
Total Common Shares Outstanding	420.73	418.49	418.49	417.47	415.39	413.16
Working Capital	-397.83	-623.63	-277.28	-371.95	765.08	1,410
Book Value Per Share	13.30	13.32	12.55	11.62	10.98	10.02
Tangible Book Value	2,341	2,384	2,894	3,216	2,964	3,124
Tangible Book Value Per Share	5.56	5.70	6.92	7.70	7.14	7.56
Buildings	2,989	2,952	586.14	585.59	627.19	588.32
Machinery	430.66	449.64	424.26	402.25	376.01	339.24
Construction In Progress	240.14	191.87	2,037	1,448	639.67	63.12

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.